EUVIMEDEUVIMED entdecken
Multizentrische Studie

Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes

María Asunción Esteve-Pastor, Juan Miguel Ruíz-Nodar, Esteban Orenes-Piñero, José Miguel Rivera-Caravaca, Miriam Quintana-Giner, Andrea Véliz-Martínez, Antonio Tello-Montoliu, Vicente PerniasEscrig, Miriam Sandín Rollán, Nuria Vicente-Ibarra, Manuel Jesús MacíasVillanego, Elena Candela Sánchez und 4 weitere

Journal of Cardiovascular Pharmacology and Therapeutics · 2018-01 · 23 (1) · 57-65

DOI: 10.1177/1074248417724869 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 09.08.2017. Verfasst von María Asunción Esteve-Pastor und 15 weiteren Autor:innen. Beteiligte Einrichtung: 1 Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Murcia, Spain. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Sociedad Española de Cardiología.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current clinical guidelines of acute coronary syndromes (ACS) recommend the use of potent antiplatelet therapy, prasugrel or ticagrelor, because both drugs consistently reduce cardiovascular events.

Purpose

The aim of this study was to examine temporal changes in the use of optimal antiplatelet therapy in patients with ACS.

Methods

A total of 1717 consecutive patients admitted for ACS in 3 tertiary hospitals from February 2014 to December 2015 were enrolled. We divided these 23 months into 4 semesters: period I (0-5 months), period II (6-11 months), period III (12-17 months), and period IV (17-23 months). Demographic, clinical, and treatment data were collected both at admission and at discharge.

Results

Treatment with clopidogrel remained constant throughout the periods (52%, 50%, 44%, and 50% for periods I, II, III, and IV, respectively), whereas a progressive increase in ticagrelor treatment was observed (15%, 25%, 26%, and 28%; P = .001). Indeed, new P2Y12 agents showed an increase from 47% at the first semester to 65% in patients with ST-segment elevation myocardial infarction (STEMI), and in patients younger than 75 years from 36% to 53%. However, for patients older than 75 years, diabetic, and patients with end-stage kidney disease, clopidogrel was the second most commonly used antiplatelet agent.

Conclusion

In this real-life registry of patients with ACS, we observed there is still a high rate of use of clopidogrel, despite guidelines recommendations, and our analyses also showed a trend toward the use of ticagrelor. Patients who received new antiplatelet agents were patients with STEMI, younger than 75 years, and with less comorbidities. However, the use of ticagrelor and prasugrel remains low, highlighting a therapeutic inertia with considerable gap between evidence-based clinical guidelines and daily clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAdenosineAge FactorsAgedClopidogrelFemaleHospitalizationHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPractice Guidelines as TopicPractice Patterns, Physicians'Prasugrel HydrochlorideProspective StudiesPurinergic P2Y Receptor AntagonistsRegistriesST Elevation Myocardial InfarctionTicagrelorTiclopidine

Stichwörter der Autor:innen

acute coronary syndromeantiplatelet agentsdiabetesrenal diseasetherapeutic inertia

Substanzen

Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsClopidogrelPrasugrel HydrochlorideTicagrelorAdenosineTiclopidine

Autor:innen und Institutionen

  • 1 Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Murcia, Spain.
  • 2 Department of Cardiology, Hospital General Universitario de Alicante, Alicante, Spain.
  • 3 Department of Cardiology, Hospital General Universitario de Elche, Alicante, Spain.

Förderung

  • Sociedad Española de Cardiología

Zitieren

APA

Esteve-Pastor, M. A., Ruíz-Nodar, J. M., Orenes-Piñero, E., Rivera-Caravaca, J. M., Quintana-Giner, M., Véliz-Martínez, A., Tello-Montoliu, A., PerniasEscrig, V., Sandín Rollán, M., Vicente-Ibarra, N., MacíasVillanego, M. J., Candela Sánchez, E., Carrillo Alemán, L., Lozano, T., Valdés, M., & Marín, F. (2018). Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 23(1), 57-65. https://doi.org/10.1177/1074248417724869

Vancouver

Esteve-Pastor MA, Ruíz-Nodar JM, Orenes-Piñero E, Rivera-Caravaca JM, Quintana-Giner M, Véliz-Martínez A, et al. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics. 2018;23(1):57-65. doi:10.1177/1074248417724869

BibTeX
@article{EstevePastor2018,
  author = {Esteve-Pastor, María Asunción and Ruíz-Nodar, Juan Miguel and Orenes-Piñero, Esteban and Rivera-Caravaca, José Miguel and Quintana-Giner, Miriam and Véliz-Martínez, Andrea and Tello-Montoliu, Antonio and PerniasEscrig, Vicente and Sandín Rollán, Miriam and Vicente-Ibarra, Nuria and MacíasVillanego, Manuel Jesús and Candela Sánchez, Elena and Carrillo Alemán, Luna and Lozano, Teresa and Valdés, Mariano and Marín, Francisco},
  title = {Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2018},
  volume = {23},
  number = {1},
  pages = {57--65},
  doi = {10.1177/1074248417724869}
}
Kostenlos starten →